Amifostine can differentially modulate DNA double-strand breaks and apoptosis induced by idarubicin in normal and cancer cells

We have previously shown that amifostine differentially modulated the DNA-damaging action of idarubicin in normal and cancer cells and that the presence of p53 protein and oncogenic tyrosine kinases might play a role in this diversity. Aim: To investigate further this effect we have studied the influence of amifostine on idarubicin-induced DNA double-strand breaks (DSBs) and apoptosis. Methods: We employed pulse-field gel electrophoresis () for the detection of DSBs and assessment of their repair in human normal lymphocytes and chronic myelogenous leukaemia K562 cells lacking p53 activity and expressing the BCR/ABL tyrosine kinase. Apoptosis was evaluated by caspase-3 activity assay assisted by the alkaline comet assay and DAPI staining. Results: Idarubicin induced DSBs in a dose-independent manner in normal and cancer cells. Both types of the cells did not repair these lesions in 120 min and amifostine differentially modulated their level — decreased it in the lymphocytes and increased in K562 cells. In contrast to control cells, amifostine potentated apoptotic DNA fragmentation, chromatin condensation and the activity of caspase-3 in leukaemia cells. Conclusion: Amifostine can differentially modulate DSBs and apoptosis induced by idarubicin in normal and cancer cells. It can protect normal cells against drug-induced DNA damage and it can potentate the action of the drug in leukaemic cells. Further studies on link between amifostine-induced modulation of DSBs and apoptosis of cancer cells will bring a deeper insight into molecular mechanism of amifostine action.Ранее нами было показано, что амифостин дифференциально модулирует ДНК-повреждающее действие идарубицина в нормальных и злокачественных клетках, и что наличие белка р53 и онкогенных тирозин киназ может иметь значение для этих различий. Цель: изучить влияние амифостина на идарубицин-опосредованные двухнитевые разрывы ДНК (DSBs) и апоптоз. Методы: мы применили гель-электрофорез в пульсирующем поле (PFGE) для выявления DSBs и изучения их репарации в нормальных лимфоцитах человека и клетках K562 хронической миелоидной лейкемии, у которых р53 неактивен и экспрессирована BCR/ABL-тирозин киназа. Апоптоз оценивали с помощью реактивов для выявления активности каспазы-3, проведения щелочного гель-электрофореза одиночных клеток и DAPI-окрашивания. Результаты: идарубицин вызывает образование DSBs в нормальных и злокачественных клетках независимо от дозы. Оба типа клеток не репарировали эти повреждения за 120 мин, при этом амифостин дифференциально молулировал уровень DSBs — уменьшал в лимфоцитах и увеличивал в K562-клетках. В отличие от контрольных клеток амифостин потенциировал апоптическую фрагментацию ДНК, конденсацию хроматина и активность каспазы-3 в лейкемических клетках. Выводы: амифостин может дифференциально модулировать DSBs и апоптоз, вызванные идарубицином в нормальных и злокачественных клетках. Он может защитить нормальные клетки от повреждения ДНК, вызванного химиопрепаратом, и в то же время потенциировать действие препарата на лейкемические клетки. Дальнейшие исследования связи между вызванной амифостином модуляцией DSBs и апоптоза опухолевых клеток позволит лучше понять молекулярные механизмы действия амифостина

Promoter methylation of cancer-related genes in gastric carcinoma

Genetic changes associated with gastric cancer are not completely known, but epigenetic mechanisms involved in this disease seem to play an important role in its pathophysiology. One of these mechanisms, an aberrant methylation in the promoter regions of genes involved in cancer induction and promotion, may be of particular importance in gastric cancer. Aim: To analyze the methylation status of eight genes: Apaf-1, Casp8, CDH1, MDR1, GSTP1, BRCA1, hMLH1, Fas in gastric cancer patients. Methods: The methylation pattern of the genes was assessed by methylation specific restriction enzyme PCR (MSRE-PCR) in gastric tumors taken during surgery of 27 patients and compared with the methylation pattern in material obtained from biopsy in 25 individuals without cancer and pre-cancerous lesions. Results: We observed a promoter hypermethylation in the Casp8, hMLH1, CDH1 and MDR1 in gastric cancer patients as compared with the controls. Additionally, we investigated the relationship between promoter hypermethylation and age, gender, smoking and gastric cancer family history. The hypermethylation of the hMLH1 gene occurred more frequently in female than in men, and the hypermethylation of the CDH1 gene was observed preferentially in smoking than in non-smoking individuals. Conclusion: The data obtained indicate that changes in DNA methylation may contribute to gastric carcinogenesis.Генетические изменения, ассоциированные с опухолью желудка, изучены не в полной мере. В то же время эпигенетические механизмы скорее всего играют ключевую роль и лежат в основе возникновения этого заболевания. Один из таких механизмов– нарушенияметилирования промоторов генов, которые регулируют злокачественнуютрансформациюи прогрессирование опухолевого процесса, может быть особенно важным в развитии рака желудка. Цель: проанализировать статус метилирования промоторов восьми генов: Apaf-1, Casp8, CDH1, MDR1, GSTP1, BRCA1, hMLH1, Fas у больных раком желудка. Методы: метилирование промоторов генов изучали с помощьюспецифической к сайтамметилирования рестрикцией с ПЦР (MSRE-PCR) на хирургическомматериале (опухоли желудка) 27 пациентов. Вкачестве контроля использовали иопсийныйматериал, полученный от 25 больных, у которых не было выявлено рака или предраковых состояний. Результаты: отмечали гиперметилирование промоторов генов Casp8, hMLH1, CDH1 и MDR1 в опухолевой ткани желудка по сравнению с контрольными образцами. Кроме того, нами была прослежена взаимосвязь между гиперметилированием промоторов генов и возрастом, полом пациентов, курением и семейной историей заболевания раком желудка. Гиперметилирование гена hMLH1 выявляли чаще у женщин, чем у мужчин, а гиперметилирование гена CDH1 — в основном у курильщиков. Выводы: полученные данные свидетельствуют о том, что метилирование ДНК может играть важную роль при развитии рака желудка

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

We have investigated the serum concentrations of interleukin-6 (IL-6) and two IL-6 family cytokines-oncostatin M (OSM) and leukemia inhibitory factor (LIF)-in 63 patients with B-cell chronic lymphocytic leukemia (B-CLL) and 17 healthy controls using the enzyme-linked immunosorbent assay (ELISA) method. Simultaneously, we measured the serum levels of the soluble forms of two subunits of the IL-6 receptor complex-ligand binding glycoprotein 80 (sIL-6R) and glycoprotein 130 (sgp130). The cytokines and receptors were evaluated in 25 untreated patients and 38 patients treated with cladribine (2-CdA), as well as in 17 healthy controls. We have correlated the serum levels of these proteins with Rai's clinical stage of the disease, the response to 2-CdA treatment and some hematological parameters. We have also evaluated the correlation of the IL-6 serum level with the concentration of OSM and IL-6 soluble receptors. IL-6 was measurable in 62/63 (98.4%), OSM in 20/25 (80%) of untreated and 14/38 (37.8%) of the treated patients. sIL-6R and sgp130 were detectable in all 63 patients and LIF in none of the CLL patients. IL-6 serum level in untreated patients was not significantly different as compared to its concentration in the control group (P>0.05). However, in the patients treated with 2-CdA the IL-6 level was significantly lower (P<0.02), and the lowest concentration was found in the patients with complete remission (CR; median 1.4pg/ml; P<0.02). The concentration of sIL-6R was significantly higher in untreated (median 61.8 ng/ml) and treated (median 50.1 ng/ml) CLL patients when compared to normal persons (median 41.2 ng/ml; P=0.04; P<0.001, respectively). There was no difference between the sIL-6R levels in the patients with CR and the healthy controls. In non-responders sIL-6R concentration was the highest and similar to its level in the untreated patients. OSM level was higher in the untreated patients (median 1.8pg/ml) than in the normal controls (median 0.0pg/ml; P<0.001) and in the CR patients (median 0.0pg/ml; P<0.03). The serum concentration of sgp130 was similar in the untreated (median 480 pg/ml) and treated (median 470 pg/ml) patients, as well as in the healthy persons (median 420 pg/ml; P>0.05). We have found significant positive correlation between the levels of sIL-6R and the lymphocytes count in CLL patients (p=0.423; P<0.001). In addition, sIL-6R and OSM serum concentrations correlated also with CLL Rai stage. In conclusion, the serum level of IL-6, OSM and sIL-6R, but not LIF and sgp130, are useful indicators of CLL activity

Anisotropic elasticity in confocal studies of colloidal crystals

We consider the theory of fluctuations of a colloidal solid observed in a confocal slice. For a cubic crystal we study the evolution of the projected elastic properties as a function of the anisotropy of the crystal using numerical methods based on the fast Fourier transform. In certain situations of high symmetry we find exact analytic results for the projected fluctuations.Comment: 6 pages, 7 figure

On a functional equation involving iterates and powers

We present a complete list of all continuous solutions f : (0,+∞)→(0,+∞) of the equation f 2(x) = γ [f (x)]αxβ, where α, β and γ > 0 are given real numbers

Human breast tissue cancer diagnosis by Raman spectroscopy

Abstract. Differences between Raman spectra of normal, malignant and benign tissues have been recorded and analyzed as a method for the early detection of cancer. To the best of our knowledge, this is one of the most statistically reliable research (67 patients) on Raman spectroscopy-based diagnosis of breast cancers among the world women population. The paper demonstrates that Raman spectroscopy is a promising new tool for real-time diagnosis of tissue abnormalities

Polish 2010 growth references for school-aged children and adolescents

Growth references are useful in monitoring a child's growth, which is an essential part of child care. The aim of this paper was to provide updated growth references for Polish school-aged children and adolescents and show the prevalence of overweight and obesity among them. Growth references for height, weight, and body mass index (BMI) were constructed with the lambda, mu, sigma (LMS) method using data from a recent, large, population-representative sample of school-aged children and adolescents in Poland (n = 17,573). The prevalence of overweight and obesity according to the International Obesity Taskforce definition was determined with the use of LMSGrowth software. Updated growth references for Polish school-aged children and adolescents were compared with Polish growth references from the 1980s, the Warsaw 1996–1999 reference, German, and 2000 CDC references. A positive secular trend in height was observed in children and adolescents from 7 to 15 years of age. A significant shift of the upper tail of the BMI distribution occurred, especially in Polish boys at younger ages. The prevalence of overweight or obesity was 18.7% and 14.1% in school-aged boys and girls, respectively. The presented height, weight, and BMI references are based on a current, nationally representative sample of Polish children and adolescents without known disorders affecting growth. Changes in the body size of children and adolescents over the last three decades suggest an influence of the changing economical situation on anthropometric indices

Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer—a case control study

XRCC2 and XRCC3 proteins are structurally and functionally related to RAD51 which play an important role in the homologous recombination, the process frequently involved in cancer transformation. In our previous work we show that the 135G>C polymorphism (rs1801320) of the RAD51 gene can modify the effect of the Thr241Met polymorphism (rs861539) of the XRCC3 gene. We tested the association between the 135G>C polymorphism of the RAD51 gene, the Thr241Met polymorphism of the XRCC3 gene and the Arg188His polymorphism (rs3218536) of the XRCC2 gene and colorectal cancer risk and clinicopathological parameters. Polymorphisms were evaluated by restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR) in 100 patients with invasive adenocarcinoma of the colon and in 100 sex, age and ethnicity matched cancer–free controls. We stratified the patients by genotypes, tumour Duke’s and TNM stage and calculated the linkage of each genotype with each stratum. Carriers of Arg188Arg/Me241tMet, His188His/Thr241Thr and His188His/G135G genotypes had an increased risk of colorectal cancer occurrence (OR 5.70, 95% CI 1.10–29.5; OR 12.4, 95% CI 1.63–94.9; OR 5.88, 95% CI 1.21–28.5, respectively). The C135C genotype decreased the risk of colorectal cancer singly (OR 0.06, 95% CI 0.02–0.22) as well as in combination with other two polymorphisms. TNM and Duke’s staging were not related to any of these polymorphisms. Our results suggest that the 135G>C polymorphism of the RAD51 gene can be an independent marker of colorectal cancer risk. The Thr241Met polymorphism of the XRCC3 gene and the Arg188His polymorphism of the XRCC2 gene can modify the risk of colorectal cancer